Department of Allergy and Immunology, Royal Children's Hospital, Melbourne, Australia; Department of Paediatrics, University of Melbourne, Melbourne, Australia; Allergy and Immune Disorders, Murdoch Childrens Research Institute, Melbourne, Australia.
Environmental and Genetic Epidemiology, Murdoch Childrens Research Institute, Melbourne, Australia.
J Allergy Clin Immunol. 2015 Mar;135(3):737-44.e8. doi: 10.1016/j.jaci.2014.11.034. Epub 2015 Jan 13.
Coadministration of a bacterial adjuvant with oral immunotherapy (OIT) has been suggested as a potential treatment for food allergy.
To evaluate a combined therapy comprising a probiotic together with peanut OIT.
We performed a double-blind, placebo-controlled randomized trial of the probiotic Lactobacillus rhamnosus CGMCC 1.3724 and peanut OIT (probiotic and peanut oral immunotherapy [PPOIT]) in children (1-10 years) with peanut allergy. The primary outcome was induction of sustained unresponsiveness 2 to 5 weeks after discontinuation of treatment (referred to as possible sustained unresponsiveness). Secondary outcomes were desensitization, peanut skin prick test, and specific IgE and specific IgG4 measurements.
Sixty-two children were randomized and stratified by age (≤5 and >5 years) and peanut skin test wheal size (≤10 and >10 mm); 56 reached the trial's end. Baseline demographics were similar across groups. Possible sustained unresponsiveness was achieved in 82.1% receiving PPOIT and 3.6% receiving placebo (P < .001). Nine children need to be treated for 7 to achieve sustained unresponsiveness (number needed to treat, 1.27; 95% CI, 1.06-1.59). Of the subjects, 89.7% receiving PPOIT and 7.1% receiving placebo were desensitized (P < .001). PPOIT was associated with reduced peanut skin prick test responses and peanut-specific IgE levels and increased peanut-specific IgG4 levels (all P < .001). PPOIT-treated participants reported a greater number of adverse events, mostly with maintenance home dosing.
This is the first randomized placebo-controlled trial evaluating the novel coadministration of a probiotic and peanut OIT and assessing sustained unresponsiveness in children with peanut allergy. PPOIT was effective in inducing possible sustained unresponsiveness and immune changes that suggest modulation of the peanut-specific immune response. Further work is required to confirm sustained unresponsiveness after a longer period of secondary peanut elimination and to clarify the relative contributions of probiotics versus OIT.
与口服免疫疗法(OIT)联合使用细菌佐剂已被提议作为治疗食物过敏的一种潜在方法。
评估包含益生菌与花生 OIT 的联合治疗方案。
我们进行了一项针对患有花生过敏的儿童(1-10 岁)的益生菌 Lactobacillus rhamnosus CGMCC 1.3724 与花生 OIT(益生菌与花生口服免疫疗法[PPOIT])的双盲、安慰剂对照随机试验。主要结局是在治疗停止后 2 至 5 周时是否诱导出持续无反应(称为可能的持续无反应)。次要结局是脱敏、花生皮试、特异性 IgE 和特异性 IgG4 测量。
共有 62 名儿童随机分组,并根据年龄(≤5 岁和>5 岁)和花生皮试风团大小(≤10mm 和>10mm)进行分层;56 名儿童完成了试验。各组的基线人口统计学特征相似。接受 PPOIT 治疗的儿童中有 82.1%达到可能的持续无反应,而接受安慰剂治疗的儿童仅有 3.6%(P<.001)。需要治疗 7 名儿童才能达到持续无反应(需要治疗人数,1.27;95%CI,1.06-1.59)。接受 PPOIT 治疗的儿童中,89.7%脱敏,而接受安慰剂治疗的儿童中仅有 7.1%脱敏(P<.001)。PPOIT 与花生皮试反应和花生特异性 IgE 水平降低以及花生特异性 IgG4 水平升高相关(均 P<.001)。接受 PPOIT 治疗的参与者报告了更多的不良事件,主要与维持家庭剂量相关。
这是第一项评估新型益生菌与花生 OIT 联合使用并评估儿童花生过敏持续无反应的随机安慰剂对照试验。PPOIT 可有效诱导可能的持续无反应和免疫变化,提示调节花生特异性免疫反应。需要进一步的工作来确认在更长的次级花生消除期后持续无反应的情况,并阐明益生菌与 OIT 的相对贡献。